ALAMEDA, Calif. & LONDON, Ontario--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today a research collaboration where Sernova will utilize AgeXs UniverCyteTM gene technology to generate immune-protected universal therapeutic cells for use in combination with Sernovas Cell PouchTM for the treatment of type I diabetes and hemophilia A. The goal is to eliminate the need for immunosuppressive medications following Cell Pouch cell transplantation.

The research collaboration will evaluate whether Sernovas pluripotent stem cell-derived pancreatic islet beta cells engineered with AgeXs UniverCyte technology can evade human immune detection. The complementary combination of technologies could enable the transplantation of therapeutic cells in patients with type I diabetes in an off-the-shelf manner using Sernovas Cell Pouch, without human leukocyte antigen (HLA) tissue matching or concurrent administration of immunosuppressive medications. With a similar intent, pluripotent stem cell-derived or adult donor-derived human Factor VIII-releasing cells modified with AgeXs UniverCyte will be evaluated in Sernovas hemophilia A program.

Under the terms of the agreement, Sernova has been granted a time-limited, non-exclusive research license by AgeX. A commercial license for Sernova to utilize UniverCyte to engineer cellular products for therapeutic and commercial purposes may be negotiated between the companies pending successful study outcomes.

The UniverCyte technology aims to mask therapeutic cells derived from pluripotent stem cells or adult donors from human immune detection to allow for off-the-shelf cellular products without the need for immunosuppressant medications which may have potent side effects, or HLA-matching between donor and patient. UniverCyte uses a novel, modified form of HLA-G, a potent immunomodulatory molecule, which in nature protects an unborn child from their mothers immune system. In almost all human cells, native HLA-G expression is silenced after birth. AgeXs modified HLA-G shows evidence of being resistant to this silencing, thereby potentially allowing for long-term, stable and high expression of the immunomodulatory effect.

Sernova plans to utilize the universal therapeutic cells generated through this research collaboration with its Cell Pouch System, a proprietary, scalable, implantable macro-encapsulation device, which, upon implantation, incorporates with tissue and forms highly vascularized chambers. These chambers become a natural environment in the body to house and favor long-term survival and function of therapeutic cells. The Cell Pouch System has shown initial safety and efficacy indicators in an ongoing Phase I/II clinical study at the University of Chicago and in a preclinical model of hemophilia A when assessed with human cells corrected to produce Factor VIII.

We are thrilled with our collaboration with Sernova, which is at the forefront of cellular therapies for diabetes and hemophilia and is already in the clinic for the former. The combination of AgeXs UniverCyte to cloak cells from a patients immune system and Sernovas Cell Pouch technologies to permit cells to function long-term upon transplantation would be a landmark for regenerative medicine. This deal marks another important step in AgeXs collaboration and licensing strategy to work with the very best people, companies and institutions in the world of regenerative medicine, said Dr. Nafees Malik, Chief Operating Officer of AgeX.

We look forward to working with AgeX and its outstanding team as we continue to identify and evaluate technologies complementary to Sernovas therapeutic platform and expand our immune protection offerings. AgeXs UniverCyte technology is a significant advancement in the field of cell therapy and a perfect fit with Sernovas Cell Pouch technologies and therapeutic pipeline with its potential benefit over current immunosuppressive strategies for regenerative medicine therapeutics, said Dr. Philip Toleikis, President and CEO of Sernova Corp.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About Sernova Corp.

Sernova Corp is developing regenerative medicine therapeutic technologies using the Cell Pouch System, a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit http://www.sernova.com.

Forward-Looking Statements for AgeX

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, there can be no assurance that Sernovas planned use of AgeXs UniverCyteTM gene technology will successfully generate immune-protected universal therapeutic cells for use in combination with Sernovas Cell PouchTM for the treatment of type I diabetes and hemophilia A or any other disease, and there can be no assurance that AgeX and Sernova will enter into a commercial license for the use of UniverCyteTM in a therapeutic or other product. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Forward-Looking Statements for Sernova

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words expects, plans, anticipates, believes, intends, estimates, projects, potential and similar expressions, or that events or conditions will, would, may, could or should occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements including those related to the potential of Univercyte combined with Sernovas technologies are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernovas management on the date such statements were made, which include our beliefs about the effect on company operations of the COVID-19 virus and conduct and outcome of discussions, clinical programs, and our clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View original post here:
AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A -...

On February 7, 2020, a 54-year-old man presented to Yanggu Peoples Hospital, Shandong, with a 4-day history of cough, chest tightness, and fever. Apart from a 2-year history of diabetes, the patient had no other specific medical history. The physical examination showed a body temperature of 38.0C, blood pressure of 141/87mmHg, and pulse of 81 beats per minute. A blood routine examination was arranged urgently, and throat swabs were collected. The result revealed that the white cell count and absolute lymphocyte count were 7.59109/L (reference range 3.5~9.5109/L) and 0.24109/L (reference range 1.1~3.2109/L), respectively; C-reactive protein (CRP), 59.64mg/L (reference range 0~10mg/L); influenza A and B virus antigen (); and routine anti-inflammation and antivirus therapy were given for supportive treatment.

On February 9, 2020, the real-time polymerase chain reaction (RT-PCR) assay confirmed that the patients specimen tested positive for COVID-19. Then, the patient was admitted to an airborne isolation unit in Liaocheng Infectious Disease Hospital for clinical observation.

On February 11, 2020, the patient felt severe shortness of breath, and the oxygen saturation values decreased to as low as 87.9%. Related laboratory results showed PH (7.46), PCO2 (26mmHg), PO2 (50mmHg), HCO3 (18.4mmol/L). The doctors decided to change the diagnosis to COVID-19 (critically severe type), and the patient was admitted to the ICU of Liaocheng Peoples Hospital for better treatment.

On February 12, 2020, the shortness of breath even got worse under the oxygen supplementation. The doctor speeded up the oxygen airflow to 45L per minute. Chest computerized tomography (CT) clearly showed evidence of pneumonia and ground-glass opacity, in the right and left lungs (Fig.1A-1A-4). According to the guideline for the diagnosis and treatment of COVID-19 [14], the patient was treated with antiviral therapy of lopinavir/ritonavir, IFN- inhalation, and also intravenous injection of levofloxacin, tanreqing capsule, xuebijing, thymosin 1, methylprednisolone, and immunoglobulin. During this time, the patient received antipyretic therapy. More treatments were conducted consisting of electrocardiograph monitoring, potassium chloride sustained-release tablets (oral, 1g per time, 2 times per day), plasma exchange and regulated intestinal microflora of patient, etc. Finally, the discomfort was released, and the oxygen saturation increased to 98%.

Chest computerized tomography (CT) images of the COVID-19 patient. A-1A-4 On February 12, ground-glass opacity (GGO) and pneumonia infiltration occurred in both the left and right lungs. Several GGO regions in each of the 5 lung lobes, and some with traction bronchiectasis; in the left lower lobe, crazy-paving pattern (GGO with superimposed inter- and intralobular septal thickening) with a few scattered consolidation and vascular dilatation were observed. B-1B-4 CT images on February 22 indicate the symptoms of the patient are slightly relieved, but the pneumonia was still significant. There were reduced regions of initial GGO, with a new area of subpleural consolidation. C-1C-4 Cell transplantation was performed on February 24. On March 1, the pneumonia infiltration faded away very much. Most of the ground-glass opacity lightened, or even disappeared. The partial area of consolidation was still observed

On February 13 to 21, the patients vital physical signs remained largely stable, apart from the development of intermittent fevers and shortness of breath.

On February 22, the patient took a turn for the worse (Fig.1B-1B-4). Considering the severe organ injury caused by an inflammatory response, hWJC adoptive transfer therapy was proposed under the advice and guidance of the specialist group. The family member and patient agreed to try hWJC adoptive transfer therapy. The therapeutic scheme was then discussed and approved by the ethics committee of the hospital, and consent forms were signed by the family member before the therapy. On February 24, the patient receives hWJC transfusion.

On March 1, the patient felt much better. The shortness of breath was significantly recovering. The CRP decreased to 27.2g/L, the absolute lymphocyte count rose to 0.66109/L, and the inflammatory factors reduced to normal levels, which indicated that the patient was recovering rapidly. On March 2, the patient meets the discharge standard, and the medical observation is canceled

Read more:
Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19...

In 2029, the Animal Stem Cell Therapy market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Animal Stem Cell Therapy market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Animal Stem Cell Therapy market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Animal Stem Cell Therapy market research study, 2018 is considered as the base year, and 2019-2029 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

The report on the Animal Stem Cell Therapy market provides a birds eye view of the current proceeding within the Animal Stem Cell Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Animal Stem Cell Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2638488&source=atm

Global Animal Stem Cell Therapy market report on the basis of market players

The report examines each Animal Stem Cell Therapy market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Animal Stem Cell Therapy market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Segment by Type, the Animal Stem Cell Therapy market is segmented intoDogsHorsesOthers

Segment by Application, the Animal Stem Cell Therapy market is segmented intoVeterinary HospitalsResearch Organizations

Regional and Country-level AnalysisThe Animal Stem Cell Therapy market is analysed and market size information is provided by regions (countries).The key regions covered in the Animal Stem Cell Therapy market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.Competitive Landscape and Animal Stem Cell Therapy Market Share AnalysisAnimal Stem Cell Therapy market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Animal Stem Cell Therapy business, the date to enter into the Animal Stem Cell Therapy market, Animal Stem Cell Therapy product introduction, recent developments, etc.The major vendors covered:Medivet Biologics LLCVETSTEM BIOPHARMAJ-ARMU.S. Stem Cell, IncVetCell TherapeuticsCelavet Inc.Magellan Stem CellsKintaro Cells PowerAnimal Stem CareAnimal Cell TherapiesCell Therapy SciencesAnimacel

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2638488&source=atm

The Animal Stem Cell Therapy market report answers the following queries:

The Animal Stem Cell Therapy market report provides the below-mentioned information:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2638488&licType=S&source=atm

Research Methodology of Animal Stem Cell Therapy Market Report

The global Animal Stem Cell Therapy market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Animal Stem Cell Therapy market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Animal Stem Cell Therapy market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

See the original post:
Coronavirus threat to global Animal Stem Cell Therapy Globally Expected to Drive Growth through 2021 - 3rd Watch News

The global Cancer Stem Cell Therapy market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Cancer Stem Cell Therapy market player in a comprehensive way. Further, the Cancer Stem Cell Therapy market report emphasizes the adoption pattern of the Cancer Stem Cell Therapy across various industries.

The Cancer Stem Cell Therapy market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

The report on the Cancer Stem Cell Therapy market provides a birds eye view of the current proceeding within the Cancer Stem Cell Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Cancer Stem Cell Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2542097&source=atm

The following manufacturers are covered:AVIVA BioSciencesAdnaGenAdvanced Cell DiagnosticsSilicon Biosystems

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAutologous Stem Cell TransplantsAllogeneic Stem Cell TransplantsSyngeneic Stem Cell TransplantsOther

Segment by ApplicationHospitalClinicMedical Research InstitutionOther

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2542097&source=atm

The Cancer Stem Cell Therapy market report offers a plethora of insights which include:

The Cancer Stem Cell Therapy market report answers important questions which include:

The Cancer Stem Cell Therapy market report considers the following years to predict the market growth:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2542097&licType=S&source=atm

Why Choose Cancer Stem Cell Therapy Market Report?

Cancer Stem Cell Therapy Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

Read more from the original source:
Addressing the potential impact of coronavirus disease (COVID-19) on Cancer Stem Cell Therapy Market 2019 key leaders analysis, Gross margin,...

Treatment with idecabtagene vicleucel (ide-cel; bb2121) led to responses in 73% of heavily pretreated patients with relapsed or refractory multiple myeloma, and complete responses (CRs) in 33%, according to topline findings from the pivotal phase 2 KarMMA trial.

Data shared during the 2020 ASCO Virtual Scientific Program demonstrated a median duration of response (DOR) of 10.7 months, and amedian progression-free survival (PFS) of 8.8 months (95% CI, 5.6-11.6).

Ide-cel demonstrated frequent, deep, and durable responses in heavily pretreated, highly relapsed/refractory patients with myeloma, said Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and professor of Medicine, Harvard Medical School. Overall, ide-cel provides an attractive option for the treatment of patients with triple-class exposed relapsed/refractory myeloma.

In March 2020, Bristol Myers Squibb andbluebird bio, Inc., the codevelopers of ide-cel, submitted a Biologics License Application (BLA) to the FDA for the use of the BCMA-targeting chimeric antigen receptor (CAR) T-cell therapy as a treatment for adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

However, earlier this month, the FDA issued aRefusal to File letter tothe companies regarding the BLA. In its initial review, the agency concluded that additional information was needed for the Chemistry, Manufacturing and Control module of the BLA. The FDA did not ask for any further clinical or nonclinical data according to the companies, which plan to resubmit the application by the end of July of this year.

The phase 2 KarMMA trial (NCT03361748) included 128 patients with relapsed/refractory multiple myeloma who received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

The median age was 61 months (range 33-78), 35% of patients had high-risk cytogenetics, 51% had high tumor burden, 39% had extramedullary disease, and 85% had 50% tumor BCMA expression. ECOG performance status was 0 (45%), 1 (53%), or 2 (2%). R-ISS disease stage was I (11%), 2 (70%), or III (16%). Patients had received a median of 6 (range, 3-16) prior antimyeloma regimens.

Ninety-four percent of patients had received 1 prior autologous stem cell transplant, and 34% had received more than 1. Eighty-eight percent of patients received bridging therapies during CAR T-cell manufacturing; however, only 4% of patients responded to the treatment. Regarding refractory status, 94% of patients were refractory to anti-CD38 antibodies and 84% were triple refractory.

Patients were treated at CAR+ T cell doses of 150 x 106 (n = 4), 300 x 106 (n = 70), or 450 x 106 (n = 54). The median follow-up was 18 months, 15.8 months, and 12.4 months, respectively. Across all patients, the median follow-up was 13.3 months. The primary end point was objective response rate (ORR), with secondary end points including CR, DOR, PFS, overall survival (OS), and quality of life.

Across all patients, the 73% ORR (95% CI, 65.8%-81.1%; P <.0001) included a 33% CR rate (95% CI, 24.7-40.9; P <.0001), a 20% very good partial response rate, and a 21% partial response rate. The overall CR rate comprised 26% of patients who achieved a CR/stringent CR (sCR) and were minimal residual disease (MRD)-negative, and 7% of patients who achieved a CR/sCR but who did not have MRD data. The median time to first response was 1 month (range, 0.5-8.8) and the median time to CR was 2.8 months (range, 1-11.8).

Durable responses were observed across all doses, said Munshi. At the dose of 450 x 106 CAR+ T cells, the ORR was 82% and the CR/sCR rate was 39%.

Clinically meaningful efficacy in terms of ORR was observed across subgroups, irrespective of age, risk categorization, tumor burden, BCMA expression level, extramedullary disease, triple-refractory status, penta-refractory status, and bridging therapy.

PFS increased as the target dose increased. At the 450 x 106 CAR+ T-cell dose, the median PFS was 12.1 months (95% CI, 8.8-12.3). The median PFS also increased by depth of response with a median of 20.2 months (95% CI, 12.3not evaluable) among patients who achieved a CR/sCR.

Munshi said the survival data are immature. At the time of the analysis, the median OS was 19.4 months (95% CI, 18.2not evaluable) and the 1-year OS rate was 78%.

Cytokine release syndrome (CRS) frequency increased with dose but was mostly low-grade, said Munshi. Overall, 84% of patients had 1 CRS event, with the majority (78%) being grade 1/2. There were 5 cases of grade 3 CRS, 1 case of grade 4, and 1 case of grade 5. The median time to onset of CRS was 1 day (range, 1-12), and the median duration of CRS was 5 days (range, 1-63). Fifty-two percent of patients received tocilizumab (Actemra) for CRS management, and 15% of patients received corticosteroids.

Neurotoxicity was mostly low grade and was similar across target doses, said Munshi. Overall, 18% of patients had 1 neurotoxicity event. There were 19 cases of grade 1/2 neurotoxicity and 4 cases of grade 3. There were no grade 4 or 5 incidents. The median time to onset of neurotoxicity was 2 days (range, 1-10), and the median duration was 3 days (range, 1-26). Two percent of patients received tocilizumab for neurotoxicity, and 8% of patients received corticosteroids.

The other significant adverse event, according to Munshi, was cytopenia91% of patients had any grade neutropenia (89% grade 3), and 63% (52% grade 3) had any grade thrombocytopenia. The median time to recovery of grade 3 neutropenia and thrombocytopenia was 2 months and 3 months, respectively, said Munshi.

There were 5 deaths within 8 weeks of ide-cel infusion2 following myeloma progression and 3 from AEs (CRS, aspergillus pneumonia, and GI hemorrhage). There was also 1 other AE-related death (CMV pneumonia) that occurred within 6 months, in the absence of myeloma progression.

Reference

Munshi NC, Anderson Jr LD, Jagannath S, et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. Presented at: 2020 ASCO Virtual Scientific Program; May 29-31, 2020. Abstract 8503.

Link:
High Rate of Responses Seen With Ide-cel in Heavily Pretreated Myeloma - Targeted Oncology

The global Cell Therapy market report presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis and key drivers. The market size of global Cell Therapy market is anticipated to grow at large scale over the forecast period. The main purpose of the study report is to give users an extensive viewpoint of the global Cell Therapy market. So that users can apply strategic processes to benchmark themselves against rest of the world. Key drivers as well as challenges of the market are discussed in the report.

Top Leading Key Players are:

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Get Sample Copy of this Report @https://www.adroitmarketresearch.com/contacts/request-sample/611

Also reports provides an in depth analysis of the Cell Therapy market with current and future trends. So that it helps to explain the upcoming investments shares in the market. To determine the overall attractiveness, Current and future trends are outlined and to single out profitable trends to gain a stronger position in the market. The report covers in detailed information regarding key drivers, restraints, risks and opportunities for the players in the global Cell Therapy market. In addition, the research report offers a Quantitative analysis of the current market. Therefore, market size estimation is provided through base year 2019 to 2020 to showcase the financial calibre of the market.

The research report on global Cell Therapy market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global Cell Therapy market. Study report covers all the geographical regions where competitive landscape exists by the players such as North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

Browse the complete report @https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

Global Cell Therapy market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

Furthermore, global Cell Therapy report covers the competitive panorama of existing and new players in the industry. Also report offers strategies initiatives of the players for the development of products. Moreover report cover in depth analysis of the market on the basis of segments. And for all the segments, actual market sizes and forecast have been provided over the forecast period. In addition, report presents quantitative as well as qualitative narration of global Cell Therapy market.

The research report is beneficial for educators, researchers, strategy managers, academic institutions and analysts. Thus report helps all types of users to identify the strategic initiatives so that they can understand how to expand the global Cell Therapy market business across the globe for the product development. Moreover, research report provides in depth analysis of all the segments which can impact on the market growth.

Additionally, the research report offers a top to bottom research based on the market size, income, deals research and key drivers. Study research reports gives the data about the innovative progression, new item dispatches, new players and late advancements in the global keyword showcase. Besides, study research report presents a far reaching learn about the market based on different fragments, for example, item type, application, key organizations and key areas, top end clients and others.

For Any Query on the Cell Therapy Market:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Link:
Cell Therapy Market 2020: Industry Analysis by Size, Share, Growth, Demands, Opportunities Trends and Forecast till 2025 - Cole of Duty

New York City, United States Since the COVID-19 infection flare-up in December 2019, the malady has spread to right around 100 nations around the world with the World Health Organization proclaiming it a general wellbeing crisis. The worldwide effects of the coronavirus sickness 2019 (COVID-19) are now beginning to be felt, and will essentially influence the Healthcare Industry in 2020.

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Pressure Guidewires MarketPressure Guidewire Market Segmented By Flat Tipped Pressure Guidewires, Flexible Tipped Pressure Guidewires Product with Pressure Wire Technology, Optical Fiber Technology Type for Hospitals, Ambulatory Surgical Centers, Independent Catheterization Labs.For More Information

Compression Therapy Devices MarketThe compression therapy market of North America is projected to escalate from US$ 2,377.8 Mn in 2014 to US$ 1,515.4 Mn, registering a CAGR of 5.4% by 2020-end.For More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsitehttps://www.persistencemarketresearch.com

See more here:
Canine Stem Cell Therapy Market Covid-19 Impact In 2026 | In-depth Analysis, Global Market Share, Top Trends, Professional & Technical Industry...